Skip to content

Stimulating Catheter for Lumbar Plexus Block: Better Postoperative Analgesia?

Stimulating Catheter for Lumbar Plexus Block: Better Postoperative Analgesia?

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02162121
Enrollment
64
Registered
2014-06-12
Start date
2014-05-31
Completion date
2016-10-31
Last updated
2017-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Replacement Arthroplasty

Brief summary

Stimulating catheters have been introduced to reduce the incidence of secondary failure after continuous peripheral nerve blocks, but they effectiveness over traditional nonstimulating catheters is still controversial. The aim of this prospective, randomized, blinded study is to detect if stimulating catheters improve postoperative compared with conventional non-stimulating catheters.

Interventions

PROCEDUREContinuous lumbar plexus: stimulating catheter

Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia.

PROCEDURESpinal Anesthesia

Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.

Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day

Ketorolac 30mg 3 times a day

PROCEDUREOpioids rescue analgesia

Buprenorphine 0,2mg twice a day if VAS\>4

DRUGMepivacaine 1%
DRUGBuprenorphine 0,2mg
DEVICEStimulong, Pajunk, Germany.
PROCEDUREContinuous lumbar plexus: non-stimulating catheter

Sponsors

ASST Gaetano Pini-CTO
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients undergoing total hip arthroplasty

Exclusion criteria

* diabetes neurological disorders coagulation disorders rheumatoid arthritis chronic opioids therapy allergy to local anesthetic

Design outcomes

Primary

MeasureTime frameDescription
Local anesthetic consumption72hEvaluation of local anesthesic consumption every 6h in first 72 postoperative hours.

Secondary

MeasureTime frameDescription
Up and Go test4th postoperative dayup and go test: time need to get up from a chair, walk for 3 meters, and come back to seat down on the chair
Opioids request72h postoperativelyOpioids consumption will be recorded throughout 72 postoperative hours
Quadriceps strengthpreoperative and 24h, 48h, 72h postoperativelyevaluate bilateral muscle strength with an isometric force dynamometer to measure the force produced during a maximum voluntary isometric contraction in a lying position by the knee flex to 90°.
Visual Analog scale (VAS) score72h postoperativelyEvaluation of VAS static and VAS dynamic during first 72 postoperative hours
Needle redirectionsDuring catheter positionDuring catheter positioning number of needle redirections necessary to found lumbar plexus are recorder.
Catheter insertion timeDuring catheter positioningTime (minutes) needed for catheter placement
postoperative nausea and vomiting (PONV)72h postoperativelyEvaluation of nausea and vomit incidence in postoperative period with scale 0 from 4

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026